



MICREOS

PRESS RELEASE

Micreos appoints Chief Medical Officer to lead clinical development of antibiotic alternative Staphitekt

Bilthoven-NL March 17, 2016

Johan Frieling (MD, PhD) has been appointed as the new Chief Medical Officer of Dutch biotech company Micreos, at a pivotal time in the company's history as it prepares for clinical trials with Staphitekt, an antibiotic alternative.

Dr. Frieling is a seasoned biopharmaceutical industry professional who acquired a wealth of clinical development experience during his 20+ years tenure. He held positions at pharmaceutical giant Bayer and biotech pioneer Genzyme. Most recently, he served as Head of Global Clinical Research at LFB Biotechnologies.

He joins at an exciting time for Micreos; the company has recently secured €12 million funding for clinical development of their antibiotic alternative, Staphitekt, into a pharmaceutical (Rx) product in several indications, including atopic dermatitis.

"Johan has successfully developed a number of biopharmaceutical products up to FDA and EMA approval. For us he is the ideal person to lead Staphitekt to market in the new indications." said Mark Offerhaus, founder and CEO of Micreos.

"It's a great time to be joining Micreos. Many people with inflammatory skin conditions like eczema, rosacea and acne are already benefiting from Staphitekt. This helps us to design the right clinical trials for new indications." Dr Frieling continues, "I look forward to sharing my knowledge and leading the clinical development of Staphitekt, ultimately helping a large cohort of patients across the globe."

Dr. Frieling has a medical degree as well as a PhD in Medical Sciences from the University of Nijmegen. He has authored many academic publications for various prestigious journals, and has presented his work at global congresses of the highest calibre in their field.

ENDS

For more information about Micreos' technology or for investor relations, visit www.micreos.com or contact Dirk de Meester on +31-646-048-503, d.demeester@micreos.com

For media enquires please contact Stuart Etherington on 02089716408, SEtherington@saycomms.co.uk



MICREOS

Notes to editors

About Micreos

Micreos develops targeted antibacterial solutions based on endolysin and phage technology as a replacement for antibiotics. Application areas include health care, veterinary medicine, the food processing industry and agriculture. The company has production facilities in Wageningen and Bilthoven. Micreos has a long-term collaboration with the Swiss technology institute ETH in Zürich and Prof. Loessner.

About Staphitekt

Staphitekt (SA.100) is the world's first endolysin licensed for human health indications. It is an enzyme which specifically targets and kills *Staphylococcus aureus*, including MRSA, leaving the beneficial bacteria intact. The working mechanism of endolysins is unrelated to that of antibiotics, meaning even bacteria resistant to antibiotics are susceptible. Staphitekt is the active compound in Gladskin, a range of creams and gels for inflammatory skin conditions, which alleviate the symptoms associated with eczema, acne and rosacea. Contrary to antibiotics Gladskin can be used as maintenance therapy as long as necessary. For more information visit: <https://www.gladskin.com/en/>

Micreos also markets FDA-approved Food Safety products: LISTEX™ (*Listeria*), and SALMONELEX™ (*Salmonella*) which are sold globally to food processing companies in the meat & poultry, cheese and fish industry. For more information: www.micreosfoodsafety.com